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Cytomegalovirus (CMV) is a beta-herpes virus present in a latent form in most people worldwide. 
In immunosuppressed individuals, CMV can reactivate and cause serious clinical complications, 
but the effect of the latent state on healthy people remains elusive. We undertook a systems 
approach to understand the differences between seropositive and negative subjects and measured 
hundreds of immune system components from blood samples including cytokines and 
chemokines, immune cell phenotyping, gene expression, ex vivo cell responses to cytokine stimuli 
and the antibody response to seasonal influenza vaccination. As expected, we found decreased 
responses to vaccination and an overall down-regulation of immune components in aged 
individuals regardless of CMV serostatus. In contrast, CMV-infected young adults exhibited an 
overall up-regulation of immune components including enhanced antibody responses to influenza 
vaccination, increased CD8+ T cell sensitivity, and elevated levels of circulating IFN-γ compared 
to uninfected individuals. Experiments with young mice infected with murine CMV also showed 
significant protection from an influenza virus challenge compared with uninfected animals, 
although this effect declined with time. These data show that CMV and its murine equivalent can 
have a beneficial effect on the immune response of young, healthy individuals, which may explain 
the continued coexistence of CMV and mammals throughout their evolution.
Introduction
Cytomegalovirus (CMV) is a common beta-herpes virus that infects most of the population 
worldwide. Primary infection often occurs during childhood and induces a strong immune 
response that, while neutralizing viral spread, does not prevent the virus from persisting in a 
latent form defined by a reversibly quiescent state in which viral genomes are maintained, 
but viral gene expression is highly restricted and no virus is produced (1). In 
immunocompromised individuals CMV can reactivate and cause substantial immunological 
changes in the host, resulting in serious clinical complications and death (2). In healthy 
individuals, CMV reactivation can also occur upon differentiation of myeloid cells, a 
reservoir for latent CMV (3), causing a state of chronic infection where the virus is 
persistently shed at low levels and for extended periods of time (4) In the immunocompetent 
host, this state of chronic infection is asymptomatic and is believed to occur intermittently, 
which appears to account for the substantial changes in the phenotype of T cells observed in 
the infected host (5) with characteristic shrinkages in naïve cells and increases in the 
memory T cell pool, with up to 10% of the latter being specific for CMV epitopes (5-9). 
Because this increase in both CD4+ and CD8+ memory T cells is also generally observed in 
aged individuals, it has been suggested that CMV promotes early immunological aging 
(10-13). However, the T cell compartment comprise only a fraction of the immune response 
and very little is known about the effect of CMV on other immune system components. 
Furthermore, the effect of these changes on immune function remains controversial (14, 15). 
For instance, in young humans and mice CMV may improve immune responses to unrelated 
antigens (16-19) whereas in older human cohorts, a number of association studies suggest 
that CMV seropositivity is linked to immune dysfunction and chronic inflammatory diseases 
including immunosenescence, cancer, cardiovascular disease, atherosclerosis, frailty and 
early mortality (11, 20-31). These observations suggest that the effect of CMV on the 
immune system may be highly dependent on an individuals’ age.
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To study the influence of age and CMV in the immune system in an unbiased fashion, we 
undertook a systems biology approach. This type of approach enables comprehensive 
characterization of biological processes taking into consideration the diversity and 
interaction of the components involved and thus, it is often utilized to study complex 
systems. We obtained peripheral blood from 91 young and older individuals and measured 
the antibody responses to seasonal influenza vaccination, as well as hundreds of immune 
system components including serum cytokines and chemokines, immune cell phenotyping 
by multiparametric flow cytometry, gene expression and high-throughput analysis of cell 
function by determining cellular responses to multiple cytokine stimuli. As expected, we 
found a down-regulation of immune cell function with age including decreased responses to 
vaccination but no effect of CMV status in the older members of the cohort. In contrast, 
young CMV-infected adults exhibited an overall up-regulation of immune function 
including enhanced antibody responses to influenza vaccination, increased CD8+ T cell 
sensitivity, and elevated levels of circulating IFN-γ compared to uninfected individuals. 
These differences may be unique to CMV since we did not observe any significant changes 
in these parameters with Epstein-Barr virus (EBV) seropositivity, another lifelong herpes 
virus infection. In parallel experiments, mice infected with murine CMV (MCMV) showed 
improved T cell responses to influenza virus challenge and dramatically reduced influenza 
virus titers. This effect was IFN-γ-dependent and declined with time. These data indicate 
that CMV can boost the immune response in younger individuals and thus has features of a 
mutualistic agent, that is, one that confers benefits on the host (32).
Results
Positive contribution of CMV to immune function in young, but not older adults
To determine the influence of age and CMV in the immune system we undertook a systems 
analysis of peripheral blood from 91 young and older individuals from the Stanford-Ellison 
cohorts (Table S1) (33-35). We focused on immunological parameters representing different 
layers of the immune system (Fig. S1) including the level of soluble cytokines and 
chemokines, cell subset frequencies and function by measuring the phosphorylation levels of 
STAT proteins in response to multiple stimulations (Fig. S2), and genome-wide mRNA 
expression (gene modules, see www.cs.unc.edu/vjojic/fluy2-upd/). A gene module 
corresponds to a set of co-expressed genes sharing transcriptional regulatory programs (33, 
36, 37).
We first determined the changes associated with CMV latency and aging across a total of 
236 baseline immune parameters. To do so, we used a classifier to identify features that best 
separate each the following categories: young CMV-uninfected (yCMV−), young CMV-
infected (yCMV+), older CMV-uninfected (oCMV−), and older CMV-infected (oCMV+) 
individuals. To minimize false positives and avoid overfitting, we conducted cross-
validation, a machine learning procedure that allows for variable selection in an unbiased 
fashion. We identified a number of features that separate with good accuracy all 
combinations of groups of individuals, with the exception of oCMV− versus oCMV+ (63% 
model accuracy compared to 60% baseline accuracy, Table S2). This indicates that in older 
individuals the effect of CMV is negligible, since oCMV− cannot be distinguished from 
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oCMV+ using the immunological parameters studied here. To isolate the contribution of age 
or CMV in young individuals, we focused on the comparisons of yCMV− vs yCMV+ 
individuals (CMV effect independent of age) and yCMV− vs oCMV− individuals (age 
effect independent of CMV). We also analyzed EBV-infected (EBV+) versus uninfected 
(EBV−) individuals, but the classification model was unable to distinguish EBV+ from EBV
− subjects (the accuracy for the logistic regression model is lower that 50%) and multiple 
regression analysis (adjusted for age and sex) showed that the most significant EBV-related 
immune feature is only detected at a False Discovery Rate (FDR) of 75% (Q = 0.75) (Fig. 
S3a), suggesting no significant correlations with the immune biomarkers measured in this 
study.
The accuracy of the computational models to distinguish yCMV− vs yCMV+ and yCMV− 
vs oCMV− were 79% and 91.7%, respectively (Table S2), indicating that aging has a more 
profound effect on the immune system than latent CMV. Strikingly, the effects of CMV and 
aging on the immunological variables measured here were almost entirely different (Fig. 1). 
The only exceptions to this were the CD8+ effector memory (TEM) and CD8+ CD28− cell 
frequencies, both being positively correlated with age and CMV. This suggests that, in 
general, the aging process and CMV infection have very different influences on the human 
immune system. Strikingly, while expression of most parameters (71%, 17/24) decreased 
with age, the majority (88%, 14/16) increased with CMV seropositivity in young individuals 
(Fig. 1 and Table S2), indicating an overall down-regulation of the immune response and 
associated parameters during aging and an up-regulation of several components of the 
immune system in young subjects with latent CMV.
In particular, we found an elevation of circulating IL-13 and IFN-γ cytokines, and higher 
CD8+ pSTAT1 and pSTAT3 responses to IL-6 in CMV+ individuals in the younger cohort 
compared to the CMV− subjects (Fig. 1). This indicates that the former group has a 
generally activated immune system involving increased Th1 and Th2 cytokines, and also 
suggests that CMV improves the CD8+ response to IL-6 in young adults. It is interesting to 
note that compared to yCMV+ subjects, the oCMV+ individuals are defective in this 
pathway (Table S2, yCMV+ vs oCMV+), which suggests a degree of adaptation to chronic 
levels of inflammatory cytokines in older CMV-infected subjects. At the gene expression 
level, the CMV effect independent of age was an up-regulation of genes associated with 
immune activation. For example, expression of module 103 (antigen processing and 
presentation, P < 0.00001 and NK cell mediated cytotoxicity, P < 0.00001) was elevated in 
yCMV+ (Fig. 1) and this module includes several KIR2 and KIR3 genes as well as GZMH 
(see http://cs.unc.edu/~vjojic/fluy2-upd/mod103.html), genes typically highly expressed in 
NK cells and in CD4+ and CD8+ T lacking CD28 (38, 39).. The expression of the gene 
module 30 was also elevated in yCMV+ (Fig. 1) and this module is composed of HLA-DOA 
and –DOB genes , which clustered with APOD, LAMC1, MIR600 among other genes. 
Intriguingly, HLA-DOA and –DOB have been recently shown to confer susceptibility to 
hepatitis B virus infection and clearance [25528575]. The age effect independent of CMV 
(yCMV− vs oCMV−) revealed down-regulation of several gene modules (Fig. 1) including 
those associated with cell cycle (module 34 and 101, P = 0.019), protein synthesis (module 
35 and 39, P = 0.0009 and P < 0.0001, respectively) amino-acid metabolism (module 43, P 
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= 0.0023), cell-death (modules 47 and 54, P = 0.0021 and P < 0.0001, respectively), the 
ubiquitination pathway (module 98, P = 0.0092), HIF1α signaling (module 101, P < 
0.0001), LXR/RXR activation, which is involved in cholesterol and lipid metabolism 
(module 102, P = 0.007) and the metabolism of carbohydrates (module 108, P = 0.00074). 
Many of these observations are consistent with a series of previous studies in diverse models 
of aging and in aged humans (40-42).
These results indicate a relatively restricted contribution of CMV to the expression of genes 
associated with immune activation and a broader contribution of age to critical aspects of 
cell function, such as cell cycle, protein synthesis and metabolism.
Negative contribution of age and positive contribution of CMV in the serological response 
to influenza vaccination
While aging typically has a negative effect on vaccination (33, 43), the influence of CMV 
infection on influenza vaccine responses has been controversial (14, 44, 45). To probe the 
immune system’s response in a standardized manner, we used seasonal trivalent inactivated 
influenza vaccination (IIV) and assayed antibody responses using the standard 
hemagglutinin-inhibition (HAI) assay at day 0 and 28±7 days after vaccination (Fig. S1) in 
two consecutive years, with 30 young individuals (20-30 years old) and 61 older individuals 
(60−>89 years old) in year 1; and 25 young and 52 older individuals in year 2. We computed 
the pre- and post-vaccine geometric mean titer (GMT) for all three strains in the vaccine and 
calculated a response score as the delta post- minus pre-GMT. As expected, a negative effect 
of age was observed in the antibody response to IIV (P < 0.0001) (Fig. 2a). Surprisingly, in 
the yCMV+ group the antibody response was higher than in yCMV− subjects (P = 0.03) 
(Fig. 2a). These CMV-related differences were not significant in the older cohort (Fig. 2a 
and b). A similar positive effect of CMV in the young (P = 0.04) but not the older cohort 
was observed in the 77 individuals who returned one year later during the 2009-2010 
influenza season (Fig. 2b). In addition, these findings were validated in an independent 
cohort of 37 young individuals recruited during the 2010-2011 influenza season (P = 0.017) 
(Fig. 2c).
These results demonstrate that in young individuals CMV infection may be beneficial since 
it improves the serological response to influenza vaccination and possibly other vaccines 
and infection.
Single nucleotide polymorphisms associated with CMV-related alteration in the CD4+ 
CD28− T cell pool
The alterations in the frequency of immune cell subsets, cytokines and other immune 
measurements observed in CMV+ subjects may contribute to improved response to 
vaccination. Indeed, yCMV+ subjects exhibited increased levels of IFN-γ, which was shown 
to mediate cross-protection in mice (16) (and see below). Notably, the CD4+ T cell response 
to CMV involves an amplification of cells lacking the CD28 receptor, which exhibit 
antigen-primed phenotypes and express cytolytic molecules including granzyme B and 
perforin. These cells emerge after cessation of the viral load; produce huge levels of IFN-γ 
and are observed only in CMV-infected persons (46). Thus, the variation in the CD4+ 
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CD28− cell subset may be important for the immune status of the individuals in our study 
and likely contribute to the variation in other immune responses. To find genetic variations 
that may confer susceptibility to important immunological alterations in CMV+ subjects, we 
employed a single nucleotide polymorphism (SNP) genotyping approach (ImmunoChip) 
which analyzes ~200,000 immune-related SNPs (47). We restricted our analyses to SNPs 
with minor allele frequency greater than 5% (116,405 SNPs) (see Methods) and focused on 
the frequency of CD4+ CD28− cells, a hallmark of CMV infection (48) and the level of 
which is not significantly affected by age. Also, these cells often arise as a result of selective 
clonal expansions of a CMV-specific T cell response (46, 49) and in our data, they showed 
the lowest p-value for comparison of variance between CMV− and CMV+ individuals (P = 
1.6 × 10−7, by one-tailed F-test). We identified 35 SNPs (on chromosomes 6, 9, 12, 14, 15, 
17 and 19) associated with the frequency of CD4+ CD28− cells, at a false discovery rate 
(FDR) lower than 5% (P < 5 × 10−6, FDR Q < 0.05) (Fig. S4). Interestingly, one of the three 
SNPs on chromosome 6 (rs7744001 (6p21.32)) is located less than 3.5kb from HLA-DQB1, 
and 22kb and 140kb from HLA-DQA1/DRA, HLA-DRB5 and HLA-DRB1 (Fig. S5), which is 
in agreement with two recent studies showing multiple genomic loci at 6p21 in the HLA 
region associated with the total lymphocyte count (50), and with the levels of CD8+ CD28− 
cells (51). A cluster of 27 SNPs spanning a region in chromosome 9 from position 
122,705,118 to 122,748,094 is located in the vicinity and within TRAF1 and 55kb 
centromeric from C5 (Fig. S6), both of which have been found to be associated with 
rheumatoid arthritis, where an elevated frequency of CD4+ CD28− T cells is a hallmark. 
These results indicate that polymorphisms in important immune-related genes could be 
responsible for the variation observed in the CD4+ T cell response to CMV.
Improved response to influenza challenge in mice previously infected with MCMV is IFN-γ 
dependent and declines with time
To determine whether the specific phenomenon observed in our human cohorts could be 
modeled in mice, we tested early and established latency with MCMV (5 and 12 weeks of 
MCMV infection, respectively) versus longstanding latency (9 months of MCMV infection) 
in C57BL/6 mice and then challenged them with the influenza A virus (IAV) strain ×31. 
Both in early and established latency, we observed better protection against influenza in the 
MCMV-infected (IAV+ MCMV+) versus the mock-infected (IAV+ MCMV−) mice at day 7 
after IAV challenge as seen by the reduced influenza viral titers in the lungs (Fig. 3a and b). 
In contrast, in older mice exposed to long-standing MCMV infection these differences were 
lost (Fig. 3c). Consistent with this observation, the influenza-specific CD8+ T cell responses 
against the three major influenza epitopes (DbPA224--233 (PA), KbPB1703-711 (PB1), and 
DbNP366-374 (NP)) in BAL cells were higher in animals with early and established latency, 
but not after long-standing latency compared with the mock-infected group (Fig. 3d-f). Our 
previous results showing increased circulating levels of IFN-γ as well as better influenza 
vaccine responses in yCMV+ subjects, suggested that the observed CMV-mediated cross-
protection might be mediated by IFN-γ. To test this, we monitored the influenza viral titer in 
the lungs and also the number of influenza-specific CD8+ T cells in IFN-γ knock-out (KO) 
or control mice challenged with IAV at 5 weeks after MCMV infection, as described earlier. 
Significantly higher viral titers and lower influenza-specific responses were observed in the 
IFN-γ KO compared to control mice (Fig 4a and b), demonstrating that IFN-γ is essential for 
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the MCMV-induced cross-protection against influenza in young mice during early MCMV 
latency and probably also contributes to this effect directly through its antiviral activity.
Discussion
In this study we identify major changes in the immune system of healthy individuals with 
age and CMV infection. Aging had a predominant and negative contribution on most 
immune parameters including the serological response to influenza vaccination, and CMV a 
positive contribution. This effect was not observed for another widespread member of the 
herpesviridae family, EBV. This observation contrasts with previous findings in mice 
showing that both murine gammaherpesvirus 68 and murine CMV, which are genetically 
similar to human EBV and CMV, can induce cross-protection against unrelated pathogens 
(16) but is consistent with studies in humans and monkeys showing that CMV induces much 
larger changes in immune cells than EBV, including the chronic activation of effector T 
cells (52). More specifically, since we show here that cross-protection in mice is IFN-γ-
dependent, it is possible that these differences are due to the high frequencies of IFN-γ-
producing CD4+ CD28− cells observed in persistent CMV but not EBV infection (53). 
Furthermore, increased percentages of circulating CD8+ CD45RA+ CD27− T cells, which 
also produce high levels of IFN-γ have been detected in CMV carriers but not after EBV or 
varicella-zoster virus infection nor after vaccination with the MMR (measles-mumps-
rubella) vaccine (54). It is plausible that the differences between the CMV and EBV-
associated changes in immune cells’ phenotype and function are due to the site of virus 
latency. For example, CMV reactivation occurs upon differentiation of myeloid precursors 
with systemic viral shedding and seemly far reaching effects, whereas latent EBV is found 
in differentiated memory B cells (55) with reactivation apparently occurring only locally 
upon recirculation of EBV-infected memory B cells into mucosa-associated lymphoid tissue 
(56). More studies are needed to address this possibility.
Young CMV+ subjects exhibited an increase in the circulating levels of Th1 and Th2 
cytokines as well as a stronger CD8+ pSTAT1 and pSTAT3 responses to IL-6 compared to 
CMV− subjects. Interestingly, older CMV+ subjects were defective in this pathway. It is 
possible that the hyper-responsive T cells observed in young CMV+’s lose the ability to 
respond to further stimuli in the older CMV+ individuals, possibly the result of longterm in 
vivo exposure to inflammatory mediators and cell desensitization. In support of this 
hypothesis, CMV infection was found to induce high levels of IL-6 (57), which may affect T 
cell responses to cytokine stimuli in vivo in a manner dependent on the duration of infection. 
This has an implications for the immune response to infection and for vaccination strategies 
in humans of different ages, for example in prime-boost regimens where the transient 
elevation of inflammatory mediators and their receptors is required for vaccine efficacy (58).
At the gene level, aging was associated with the reduced expression of genes participating in 
critical aspects of cell function, such as cell cycle, protein synthesis, metabolism, autophagy 
and the stress response, which is consistent with a series of previous studies in diverse 
models of aging and in aged humans (40-42). In contrast, the higher expression of module 
103 in yCMV+ versus yCMV− could be attributed to the known CMV-associated immune 
activation observed in infected individuals [20632887]. In agreement with the negative 
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contribution of age and positive contribution of CMV to the immune components studied 
here, vaccine responses were reduced in older subjects and improved in young CMV-
infected subjects. Whereas vaccine responses are known to be reduced in aging populations, 
the effect of CMV has been controversial, with some studies in older adults showing a 
negative effect of CMV while others showed no difference in CMV+ vs CMV− subjects 
(14, 44, 45). Of note, in young individuals, a negative association between the CMV 
antibody titer and the serological response to the influenza vaccine was found in one study; 
however this effect was weak (R = 0.16) and observed only for one out of four strains of the 
virus (60). In contrast, our analysis takes into account the response to all influenza strains in 
the vaccine for a given year and makes use of longitudinal and validation cohorts as well. 
Thus, our results indicate that CMV has no apparent effect on the serological response to 
influenza vaccination in older individuals and is consistent with a recent report analyzing 
more than 700 older subjects in long-term care facilities (44). Also in our studies CMV 
clearly boosts the immune responses of younger individuals, since yCMV+ subjects 
exhibited elevated serum levels of IFN-γ, stronger CD8+ T cell responses to cytokine stimuli 
and elevated antibody responses to the influenza vaccine. Consistent with these results, mice 
infected with MCMV showed a greater response to influenza challenge that is IFN-γ 
dependent and wanes with time in infected animals, much as older humans show no benefit. 
These results are consistent with longstanding experiments termed “heterologous immunity” 
in mice where infection with one pathogen can enhance the response to another (16, 61) and 
also has parallels with human work in which vaccination strategies directed against a 
specific pathogen has been shown to decrease mortality to different infectious diseases 
(62-64)
Other mechanisms can also be implicated in the CMV-mediated cross-protection. For 
example, Welsh and colleagues showed a degree of cross-reactivity of CD8+ T cell epitopes 
between influenza and CMV in mice and between influenza and EBV in humans (61). 
Furthermore, recently Su et al. (2013) have proposed that T cell cross-reactivity could be a 
factor based on the observation that healthy adults can have large numbers of memory 
phenotype CD4+ T cells specific for viral epitopes to which those individuals had never 
been exposed (65). However, we note that heterologous cross-reactivity has been directly 
examined for HCMV-specific responses (9) and was found to be rare, arguing against this 
mechanism in this situation. In addition, in this study, we did not find influenza-specific 
cells in the lung during the early stages of MCMV infection when IFN-γ-producing MCMV-
specific cells were present suggesting that cross-protection in MCMV+ mice is not due to 
cross-reactivity in our system. Nonetheless, there may be other T cell epitopes or antibodies 
that are cross-reactive, which were not assessed here and that could contribute to the 
protective response.
Alternatively, the presence of high levels of circulating IFN-γ in young humans and mice 
infected with CMV strongly suggests that a by-stander effect is one mechanism of 
crossprotection, as the elimination of this gene shows that that this cytokine is essential for 
the protective effect. Also, in agreement with our observations in both humans and mice, in 
one study CMV-induced cross-protection to a bacterial infection in young mice that is lost in 
older animals (17).
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In conclusion, these data demonstrate that the effects of CMV infection and aging on the 
immune system are almost entirely independent of each other, and offer no support for the 
hypothesis that this virus accelerates immunosenescence. In addition, and quite 
unexpectedly we found that CMV infection enhances the immune responses of younger 
adults, as it also in an inbred mouse model. The fact that it did not enhance the responses of 
older adults indicates that this effect requires a robust immune system, which is interesting 
in that it largely confines the benefits of infection to those of child-bearing age. Finally, 
while CMV is clearly a pathogen for immunodeficient individuals and some infants, the data 
presented here indicate that it is beneficial to a great many more people.
Materials and Methods
Study design, subjects and sample collection
Ninety-one healthy donors (ages 20 to >89) were enrolled in an influenza vaccine study at 
the Stanford-LPCH Vaccine Program during the fall of 2008, of which eighty-nine 
completed the study (33). The validation study consisted of the 77 individuals who returned 
during the fall of 2009 and an additional independent cohort of 37 individuals vaccinated in 
another study during the 2010 and 2011 influenza seasons. Given this sample size and 6 
related tasks of sizes corresponding to classification tasks between 4 age/cmv combinations, 
an effect size exceeding 0.5 is detected with probability 73.03%. We synthesized data with 
randomly distributed weights across 6 tasks such that rank of weight matrix is 2. We 
generated 100 such synthetic datasets. We run our method 100 times on these datasets. We 
computed power of our method to detect an effect in excess of 0.5. One outlier for cytokine 
data was removed from the analysis. Since all the individuals were vaccinated, no 
randomization or blinding was done for this study. The protocol for this study was approved 
by the Institutional Review Board of the Research Compliance Office at Stanford 
University. Informed consent was obtained from all subjects. All individuals were 
ambulatory and generally healthy as determined by clinical assessment. Volunteers had no 
acute systemic or serious concurrent illness, no history of immunodeficiency, nor any 
known or suspected impairment of immunologic function, including clinically observed 
liver disease, diabetes mellitus treated with insulin, moderate to severe renal disease, blood 
pressure >150/95 at screening, chronic hepatitis B or C, recent or current use of 
immunosuppressive medication. In addition, none of the volunteers were recipients or 
donors of blood or blood products within the past 6 months and 6 weeks respectively nor 
showed any signs of febrile illness on day of enrollment and baseline blood draw. Peripheral 
blood samples were obtained at day 0 (pre-vaccine), and 28±7 days after receiving a single 
intramuscular dose of trivalent seasonal influenza vaccine Fluzone (Sanofi pasteur). Each 
dose of the vaccine contained 15 µg HA each of H1N1, H3N2 and B strains of the virus. 
Whole blood was used for gene expression analysis (below). Peripheral blood mononuclear 
cells (PBMC) were obtained by density gradient centrifugation (Ficoll-Paque) and frozen 
at −80°C for 24-48 hrs before transferring to LN2. Serum was separated by centrifugation of 
clotted blood, and stored at −80°C before use. Whole blood, PBMC or serum from the first 
visit (baseline - day 0) was processed and used for determination of gene expression, 
leukocyte subset frequency, signaling responses to stimulation, serum cytokine and 
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chemokine levels, and CMV and EBV serostatus. Serum samples from day 0 and day ~28 
were used for HAI titer determination.
Determination of CMV and EBV seropositivity
Determination of CMV and EBV seropositivity was conducted by ELISA using the 
cytomegalovirus (CMV) IgG ELISA kit (Calbiotech, cat. # CM027G). Serum samples were 
thawed at room temperature and dilutions were prepared according to the manufacturer’s 
recommendations. Calculation of results was done based on the controls provided by the 
vendor. Six individuals could not be classified because they exhibited an antibody index 
between 0.9 and 1.1 (“borderline positive” according to the manufacturer). The category 
(seropositive versus seronegative) for these unclassified individuals was imputed using the 
“Impute” package (R Bioconductor), which performs nearest neighbor averaging based on 
the entire cohort’s immune measurements and gene expression values.
Whole blood microarray analysis of gene expression
Total RNA was extracted from PAXgene blood RNA tubes (PreAnalytiX) using the 
QIAcube automation RNA extraction procedure according to the manufacturer’s protocol 
(Qiagene). The amount of total RNA, and A260/A280 and A260/A230 nm ratios were 
assessed using the NanoDrop 1000 (Thermo Fisher Scientific). RNA integrity was assessed 
using the Agilent 2100 Bioanalyzer (Agilent Technologies). For each sample, 750 ng of total 
RNA were hybridized to Beadchips (HumanHT-12v3 Expression Bead Chip, Illumina) that 
contains 48,771 probes for around 25,000 annotated genes. The hybridized Beadchips were 
scanned on an Illumina BeadScan confocal scanner and analyzed by Illumina's 
GenomeStudio software, version 2.0. After checking the quality of each individual array, the 
Feature Extraction Files were imported into R Bioconductor and analyzed using the 
Beadarray package for probe filtering, quantile normalization, replicate probe 
summarization and log2 transformation. The original microarray probelevel data files were 
entered into the GEO repository under accession number GSE41080.
Leukocyte subset frequency determination
PBMC were thawed in warm media, washed twice and stained with three separate 
antihuman antibody cocktails containing: (1) anti-CD3 AmCyan, CD4 Pacific Blue, CD8 
APCH7, CD28 APC; (2) CD3 AmCyan, CD4 Pacific Blue, CD8 APCH7, CD27 PE, 
CD45RA PE-Cy5; (3) CD3 AmCyan, CD19 Alexa Fluor700, CD56 PE, CD33 PE-Cy7, 
TCR APC, all reagents from BD Biosciences. Additional information for these antibodies 
can be found on ImmPort (https://immport.niaid.nih.gov/) under accession number SDY212. 
Incubation with antibodies was performed for 40 min at 4ºC. Cells were washed with FACS 
buffer (PBS supplemented with 2% FBS and 0.1% Na Azide), and resuspended in 200 µL 
FACS buffer. Data was collected using DIVA software in an LRSII instrument (BD 
Biosciences). Analysis was performed using FlowJo 8.8.6 by gating on live cells based on 
forward vs side scatter profiles, then using double gating for singlet discrimination, followed 
by cell subset-specific gating.
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Phosphorylation of intracellular proteins by phosphoflow analysis
Cells were thawed in warm media and rested at 37ºC in RPMI with 10% FBS. Cells were 
then distributed in 96-deep well blocks (2 ml) and stimulated with IFN-γ, IL-2, IL-6, IL-7, 
IL-10 or IL-21 at 50 ng/ml or with 104 U/ml IFN-α for 15 minutes. After stimulation, cells 
were immediately fixed with 1.5% PFA for 10 min at room temperature, washed with an 
excess of plain PBS and permeabilized with 95% ice-cold methanol for 20 min on ice. 
Different stimulus conditions were barcoded using a 3×3 matrix with Pacific Orange and 
Alexa Fluor 750 (Invitrogen Corp) at 0.03 and 0.04 µg/ml for low and 0.2 and 0.3 µg/ml for 
high staining, respectively. Incubation with barcoding dyes was performed at 4ºC for 30 
min. After several washes with FACS buffer, stimulated and barcoded cells were pooled into 
single tubes and stained for 30 min at 4ºC with an antibody cocktail containing anti-pSTAT1 
Alexa Fluor 488, pSTAT3 Alexa Fluor 647, pSTAT5 PE, CD3 Pacific Blue, CD4 PerCP-
Cy5.5, CD20 PerCP-Cy5.5 and CD33 PE-Cy7 (all from BD Phosflow). Additional 
information for these antibodies can be found on ImmPort (https://immport.niaid.nih.gov/) 
under accession number SDY212. After washing, cells were resuspended in FACS buffer 
and acquisition was performed on an LSRII instrument (BD Biosciences). Data were 
collected using DIVA software. Data analysis was performed using FlowJo 8.8.6. by gating 
on live cells, then using double gating for singlet discrimination, followed by cell subset 
specific gating. Phosphorylation of STAT1, 3, and 5 proteins in B cells, CD4(+) or CD4(+) 
CD3(+) T cells or monocytes was analyzed by deconvolution of stimuli-specific gating. 
Baseline levels and fold increase between stimulated and unstimulated conditions were 
calculated using the 90th percentile fluorescence intensity of the pSTAT1, 3, or 5 signals.
Phosphorylation of Akt and PLC-γ was assessed in B cells by cross-linking of the B cell 
receptor. After resting PBMC samples at 37°C (as conducted for cytokine stimulations), 
cells were distributed in V-bottom 96-well plates at 0.5×106 cells per well, and incubated for 
4 min at 37ºC in CO2 incubator with anti-IgM and anti-IgG both at 10 µg/ml (BD 
Biosciences) and 3% H2O2 for phosphatase inhibition. Cells were then fixed with 1.5% 
PFA for 10 min at room temperature. After washing twice with plain PBS, cells were 
permeabilized by 20 min incubation in 95% ice-cold methanol. Cells were then washed with 
FACS buffer and stained with an antibody cocktail containing: CD3 Pacific Blue, CD20 
PerCp Cy5.5, CD27 PE Cy7, PLGγ2 (BD Biosciences) and pAkt-S473 Alexa Fluor 488 
(Cell Signaling Technologies, Danvers MA). After 30 min incubation at 4ºC, cells were 
washed in FACS buffer and analyzed by flow cytometry (as for cytokine stimulation). 
Median fluorescence intensity was recorded and used for the calculation of baseline levels of 
phosphorylated proteins and fold increase after BCR stimulation. Additional information for 
all the antibodies used in this study can be found on ImmPort (https://
immport.niaid.nih.gov/) under accession number SDY212.
Serum cytokine levels determination
Cytokines were measured using a Luminex system (Luminex Corp). 50-plex kits were 
purchased from Millipore and used according to manufacturer’s recommendations with 
modifications as described below. Briefly, serum samples were mixed with antibodylinked 
polystyrene beads on 96-well filter plates and incubated at room temperature for 2 h 
followed by overnight incubation at 4ºC. Plates were then vacuum filtered and washed twice 
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prior to 2 h incubation with biotinylated detection antibody. Samples were filtered as above, 
washed twice and incubated with streptavidin-PE for 40 min, then filtered and washed twice 
again before resuspending in reading buffer. Each sample was measured in duplicate. Plates 
were read using a Luminex LabMap200 instrument with a lower bound of 100 beads per 
sample per measured cytokine. The Luminex LabMap200 outputs the fluorescence intensity 
of each bead measured for a given cytokine in a sample. For each well, we considered the 
median fluorescence intensity (MFI) of all beads measured for a given cytokine and 
averaged the MFI of the two replicates. Values were normalized to a control sample ran in 
each of the plates.
Hemagglutination inhibition assay
The HAI assay was performed on sera from day 0 and day 28 using a standard technique 
(66); serially diluted 25-µl aliquots of serum samples in PBS were mixed with 25-µl aliquots 
of virus matching the vaccine strain composition for that years, corresponding to 4 HA units, 
in V-bottom 96-well plates (Nunc) and incubated for 30 min at room temperature. At the 
end of the incubation, 50 µl of 0.5% chicken red blood cells was added and incubated for a 
minimum of 45 min before reading for HAI activity. The HAI titer of a given sample was 
defined as the reciprocal of the last serum dilution with no HA activity. A titer of 5 was 
assigned to all samples in which the first dilution (1:10) was negative. The geometric mean 
titer (GMT) to all three strains in the vaccine was computed for each individual. Wilcoxon 
rank-sum test was used to compare responses across age groups. To estimate vaccine 
response in young and older CMV− and CMV+, post-vaccination GMT was subtracted from 
pre-vaccination GMT (delta post-pre) and Wilcoxon rank-sum test was used to compare 
vaccine responses between age and CMV infection categories.
Mice and virus infections
Female 5- to 6-week-old control C57BL/6 and IFN-γ-knockout mice were obtained from 
Jackson laboratories. All mice were cared for under specific pathogen-free conditions in an 
approved animal facility at St Jude Children’s Research Hospital (SJCRH). All animal work 
was reviewed and approved by the appropriate institutional animal care and use committee 
at SJCRH (protocol #098) following guidelines established by the Institute of Laboratory 
Animal Resources and approved by the Governing Board of the U.S. National Research 
Council. The mouse-adapted influenza A virus HKx31, was grown in the allantoic fluid of 
10-day-old embryonated chicken eggs (SPAFAS). The MCMV Smith strain (ATCC) was 
grown in mouse embryonic fibroblasts and passaged through BALB/c mice, where 
infectious virus was extracted from salivary glands at day 12 after infection. For MCMV 
virus infections, mice were infected intraperitoneally with 4×104 PFU of MCMV. For co-
infections, at the indicated time after MCMV infection, avertin (2,2,2-tribromoethanol)-
anesthesized animals were challenged intranasally with 1×106 EID50 of HKx31. Mice were 
considered in early latency at >5 weeks, established latency at 12 weeks, and long-standing 
latency at 9 months after MCMV infection.
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BAL fluid was recovered from infected animals challenged with 1×106 EID50 of HKx31 at 
the indicated time points. BAL samples were obtained by intra-tracheal HBSS wash in 
individual mice as described previously (67). Cells in the BAL were collected by 
centrifugation following standard procedures. For quantification of influenza in infected 
lungs, snap-frozen lungs were stored at −80°C until further processing.
Tetramer and Phenotypic Staining of CD8 T Cells
Influenza A peptides DbPA224-233 (SSLENFRAYV), KbPB1703-711 (SSYRRPVGI), and 
NP366–374 (ASNENMETM), and MCMV peptides M45985-993 (HGIRNASFI), m139419-426 
(TVYGFCLL) and M38316-323 (SSPPMFRV) were synthesized by the Hartwell center, 
SJCRH. Class I monomers (H-2Db and H-2Kb MHC class I glycoprotein complexed with 
the influenza A virus (PA, PB1, NP) were synthesized through a collaboration with the 
Trudeau Institute and multimerized at SJCRH. Staining was done as described previously 
(68).
Quantification of IAV in infected lung tissue
Tissues were disrupted by chopping with scissors, homogenized and centrifuged at 10,000 
rpm for 15 minutes. Lung homogenates were titered by plaque assay on Madin-Darby 
canine kidney (MDCK) cells. Near confluent 25-cm2 monolayers of MDCK cells were 
infected with 1 ml of homogenate or dilution of homogenate (in general, six tenfold 
dilutions of lungs were tested) for 1 h at 37°C. Cells were washed with PBS, 3 ml of MEM 
containing 1 mg/ml l-1-tosylamido-2-phenylethyl chloromethyl ketone-treated trypsin 
(Worthington Biochemical) 0.9% agarose was added, and cultures were incubated at 37°C 
with 5% CO2 for 72 h. Plaques were visualized with crystal violet.
Single-nucleotide polymorphism assay
All samples were genotyped using the custom designed ImmunoChip array (Illumina). The 
ImmunoChip array is focused on GWAS reported risk loci for immune-mediated diseases 
and includes 186 risk loci covered by 196,524 SNPs. Genotyping arrays were processed 
using 400ng of genomic DNA according to the manufactures protocols. Genotype calls were 
generated using the Gentrain2 Algorithm implemented in Illumina GenomeStudio software.
Statistical analysis of experiments conducted in mice
Data were analyzed using Prism 5.0 software (GraphPad). Experiments were repeated two to 
three times as indicated. We tested for homo vs heteroscedasticy (equal vs unequal variance) 
of each group of mice (CMV vs mock-infected) by the Breusch-Pagan test using the R 
package “lmtest” (http://cran.at.r-project.org/web/packages/lmtest/lmtest.pdf) and found that 
the groups had equal variance. The data presenting the differences between the groups were 
assessed using two-tailed unpaired Student t tests or by twoway ANOVA with Bonferroni 
post hoc settings. P < 0.05 indicates that the value of the test sample was significantly 
different from that of relevant controls. The Fisher’s combined probability test (69) was 
used for analysis of influenza-specific CD8+ T cell responses. To ensure reproducibility of 
our findings, we conducted three independent experiments with 4-6 mice that were 
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randomized in each group for each experiment for the early versus long-standing latency 
experiments; and two independent experiments with 3-5 mice that were randomized in each 
group for the IFN-γ-KO versus wild-type mice experiments. No blinding was done for these 
experiments.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Different immunological profiles in aging versus CMV seropositivity
The contribution of age and CMV to immunological and gene expression profiles was 
estimated by a combination of nuclear norm and the Elastic net methods (see Methods). The 
magnitude of the regression coefficients used to separate the classes yCMV− and oCMV− 
(CMV-independent age effect) or yCMV− and yCMV+ (age-independent CMV effect) are 
shown in light and dark grey bars, respectively. Only two parameters, the frequency of 
CD8+ CD28− and CD8+ TEM cells, overlapped between these classification tasks. 14/16 
(87.5%) of the parameters used to separate the yCMV− from yCMV+ classes were up-
regulated in CMV, in contrast, the majority of parameters used to separate the yCMV− from 
oCMV− classes (16/23, 69.5%) were down-regulated in aging.
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Figure 2. Young but not old CMV+ individuals have a better response to influenza vaccination
The geometric mean titer (GMT) for all three strains in the vaccine was calculated for each 
individual in the study and a standardized score (delta (Δ) post-pre GMT) for response was 
computed as described in Methods (y-axis). A higher response is observed in yCMV+ 
compared to yCMV− in the first (a) and second (b) year, as well as in an independent 
validation study conducted during the 2010-2011 influenza season (c). No significant 
differences were observed between oCMV− and oCMV+. Green bars = CMV-, yellow bars 
= CMV+. The age ranges for young and older individuals were 20-30 and 60->89 years, 
respectively (a); 22-32 (young) and 62->89 (older) years (b) and 19-44 years old (c).
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Figure 3. Reduced viral titer and enhanced IAV-specific CD8+ T cell responses in early and 
established but not long-standing MCMV latency
Groups of C57BL/6 mice were mock infected or infected with 4×104 PFU MCMV Smith 
strain i.p. and challenged with 106 EID50 of IAV ×31 i.n. 5 weeks (early latency) (a and d), 
12 weeks (established latency) (b and e) or 9 months (long-standing latency) later (c and f). 
Seven days after IAV infection, influenza viral titer was determined (upper panel) and IAV-
specific T cells were enumerated from the BAL of IAV+ MCMV− (MCMV−) or IAV+ 
MCMV+ (MCMV+) mice by tetramer staining for NP, PA and PB1-specific responses. Data 
are representative of three independent experiments with 4-6 mice per group in each 
experiment. Significance was determined by t-test for viral titer and using the Fisher’s 
combined probability test for comparison of specific T cell responses.
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Figure 4. The effect of MCMV on cross-protection against influenza is IFN-γ-mediated
Groups of C57BL/6 mice or IFN-γ-deficient mice (on the C57BL/6 background) were mock 
infected or infected with 4×104 PFU MCMV Smith strain i.p. and challenged 5-6 weeks 
later with 106 EID50 of IAV x31 i.n. (a) IAV lung viral titers from control (wild-type, WT) 
or IFN-γ-deficient co-infected (IAV+ MCMV+) mice were determined at day 7 after IAV 
infection in early MCMV latency (>5 weeks). (b) IAV-specific CD8+ T cells were 
enumerated from the BAL of WT and IFN-γ-deficient MCMV and IAV co-infected mice by 
tetramer staining for NP, PA and PB1-specific responses, 7 days after IAV infection. 
Significance was determined by t-test. Data are representative of two independent 
experiments with 3-5 mice per group. Significance was determined by t-test for viral titer 
and using the Fisher’s combined probability test for comparison of specific T cell responses.
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